City
Epaper

Eli Lilly Advance Weight Loss Pills Enters Phase Three Clinical Trials in India

By Lokmat English Desk | Published: March 29, 2024 10:30 AM

Eli Lilly, a US based pharmaceutical company, is spearheading the development of a potential game-changer in the weight-loss industry ...

Open in App

Eli Lilly, a US based pharmaceutical company, is spearheading the development of a potential game-changer in the weight-loss industry with its oral drug called Orforglipron. The drug, currently undergoing phase three clinical trials in India, aims to offer an alternative to injectable weight-loss medications for individuals with type-two diabetes and obesity or overweight at increased cardiovascular risk.

Orforglipron's advanced-stage trials involve 120 participants across 12 sites in India, focusing on assessing its safety and efficacy compared to insulin glargine. Preliminary research from phase-two trials indicates that the drug, taken orally once daily, has shown promising weight-loss results comparable to injectable medications like Wegovy (semaglutide) or Saxenda (liraglutide) from Novo Nordisk.

The Indian market has witnessed the introduction of oral forms of semaglutide, such as Rybelsus, for treating type two diabetes, but injectable counterparts like Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound boast superior weight-loss outcomes. However, these injectables are not yet available in India due to ongoing clinical trials and regulatory processes.

Eli Lilly's global CEO, David Ricks, expressed optimism about orforglipron's potential, citing its convenience and efficacy, especially in a country like India with a significant obesity burden. The drug's success could alleviate the supply shortages currently affecting injectable weight-loss drugs.

Medical experts anticipate better adherence to orforglipron due to its oral administration, offering a more comfortable alternative to injections. With Eli Lilly and Novo Nordisk competing to capture a substantial share of the global anti-obesity drugs market, estimated to exceed $100 billion by 2030, India's anti-obesity drugs market is also witnessing robust growth, reaching Rs 474 crore in January.

As orforglipron progresses through clinical trials, its potential to revolutionize weight-loss treatment could have far-reaching implications for individuals battling obesity and related health conditions worldwide.

Tags: Eli Lilly and CompanyWeight loss programsWeight Loss PillsHealth
Open in App

Related Stories

HealthDiet Tips for Indians: Reduce Oil and Sugar, Say No To Protein Supplements

HealthWhat is West Nile Fever Spreading in Kerala? Here's What You Need to Know

HealthGood News! Scientists Develop All-in-One Vaccine Effective Against Current and Future Coronavirus Variants

HealthFrom Chocolate to Salty Snacks: Here Are Types of Cravings and The Deficiencies They Indicate

TechnologyApple Watch Saves Delhi Woman's Life by Detecting Abnormal Heart Rhythm

Health Realted Stories

HealthTamil Nadu bans 23 'dangerous' dog breeds

HealthKerala Govt Medical Officers Association protests Thiruvananthapuram Collector's 'diktats'

HealthSimple oral rinse can detect gastric cancer early, shows study

HealthEndoscopy exposes healthcare workers to toxic smoke equal to 1 cigarette per procedure

HealthNovel AI tool to instantly help assess self-harm risk